
HealthEquity (HQY) Stock Forecast & Price Target
HealthEquity (HQY) Analyst Ratings
Bulls say
HealthEquity Inc. demonstrated strong financial performance with a 13% year-over-year increase in custodial revenue, contributing to an impressive adjusted EBITDA margin of 44.0%, reflecting a 466 basis point improvement compared to the previous year. In the most recent quarterly report, total revenue rose 7.2% year-over-year to $322.2 million, surpassing both estimates and consensus expectations, driven largely by custodial revenue growth. The company's total accounts also increased by 5.0% year-over-year to 17.280 million, highlighting the expansion in its consumer-directed benefit accounts and underscoring the positive momentum in customer engagement and revenue generation.
Bears say
HealthEquity's stock outlook remains negative due to its shares trading at 6.4x FY/26 revenue estimates and 15.1x adjusted EBITDA estimates, which are significantly lower than its high-growth SaaS peer group averages of 7.6x and 29.7x, respectively. Additionally, the company's financial performance has been impacted by a one-time legal settlement costing $30 million, indicating potential vulnerabilities in operational stability. Despite slight upward revisions in revenue and adjusted EBITDA estimates, the overall growth projections and current valuation metrics suggest a lack of competitive positioning relative to its peers, raising concerns for future performance.
This aggregate rating is based on analysts' research of HealthEquity and is not a guaranteed prediction by Public.com or investment advice.
HealthEquity (HQY) Analyst Forecast & Price Prediction
Start investing in HealthEquity (HQY)
Order type
Buy in
Order amount
Est. shares
0 shares